Endomorphin-2 at High Doses Causes Pain Through Dynorphin Release — Turning Painkiller Into Pain Maker
At high spinal doses, endomorphin-2 paradoxically produced pain (anti-analgesia) by triggering dynorphin release, which then activated NMDA receptors — revealing how excessive opioid signaling can flip from pain relief to pain generation.
Quick Facts
What This Study Found
High-dose intrathecal endomorphin-2 produced anti-analgesia through spinal dynorphin release activating NMDA receptors, demonstrating a dose-dependent flip from opioid analgesia to opioid-induced pain generation.
Key Numbers
How They Did This
Animal study. Intrathecal endomorphin-2 at escalating doses. At high doses (1.75-35 nmol), anti-analgesia measured. Anti-dynorphin antibodies and MK-801 (NMDA blocker) used to dissect the mechanism.
Why This Research Matters
Opioid-induced hyperalgesia (more pain from more opioids) is a major clinical problem. This study reveals the mechanism: excess opioid triggers dynorphin → NMDA activation → pain. Understanding this guides clinical opioid dosing.
The Bigger Picture
The paradox of opioids causing pain at high doses has plagued clinical medicine. This dynorphin-NMDA mechanism explains the phenomenon and suggests combination therapy (opioid + NMDA blocker) could prevent it.
What This Study Doesn't Tell Us
Mouse study with intrathecal injection. The dose range where the flip occurs may differ in humans.
Questions This Raises
- ?Could NMDA antagonists (ketamine) prevent opioid-induced hyperalgesia?
- ?Is this dynorphin mechanism responsible for OIH in chronic pain patients?
- ?Would lower opioid doses plus NMDA blockers achieve better pain relief?
Trust & Context
- Key Stat:
- Painkiller → pain maker At high spinal doses, the opioid endomorphin-2 flipped from reducing pain to CAUSING it through dynorphin-NMDA signaling — the mechanism of opioid-induced hyperalgesia
- Evidence Grade:
- Preliminary animal evidence with clear dose-dependent flip and mechanistic dissection through selective blocking.
- Study Age:
- Published in 2003. The dynorphin-NMDA mechanism of OIH has been confirmed and informs clinical ketamine co-therapy for opioid patients.
- Original Title:
- Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 307(3), 1135-41 (2003)
- Authors:
- Wu, Hsiang-En(5), Sun, Han-Sen(3), Darpolar, Moses, Leitermann, Randy J, Kampine, John P, Tseng, Leon F
- Database ID:
- RPEP-00874
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can painkillers cause more pain?
Yes — this study proves it at the molecular level. At high doses, the opioid endomorphin-2 triggered dynorphin release which activated NMDA pain receptors, flipping from pain relief to pain generation.
What can be done about this?
NMDA blockers (like ketamine) can prevent the dynorphin-NMDA pain flip. This is already used clinically — low-dose ketamine alongside opioids prevents opioid-induced hyperalgesia.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00874APA
Wu, Hsiang-En; Sun, Han-Sen; Darpolar, Moses; Leitermann, Randy J; Kampine, John P; Tseng, Leon F. (2003). Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.. The Journal of pharmacology and experimental therapeutics, 307(3), 1135-41.
MLA
Wu, Hsiang-En, et al. "Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.." The Journal of pharmacology and experimental therapeutics, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Dynorphinergic mechanism mediating endomorphin-2-induced ant..." RPEP-00874. Retrieved from https://rethinkpeptides.com/research/wu-2003-dynorphinergic-mechanism-mediating-endomorphin2induced
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.